{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-029588","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2026-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.616037+00:00","generated_at":"2026-05-15T10:56:43.052860+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ArriVent to present preclinical data on firmonertinib and ARR-002 at AACR 2026","bullets":["Firmonertinib preclinical data shows high potency and brain penetrance; supports ongoing Phase 3 in EGFR ex20ins NSCLC.","ARR-002 (MUC16/NaPi2b ADC) shows superior in vivo efficacy vs single-target ADCs in OVCAR-3 xenograft model.","ARR-002 demonstrates favorable tolerability in cynomolgus monkeys with reversible hematologic findings.","ARR-002 also selected for oral presentation at AACR Clinical Research Mini Symposium by Aarvik."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-029588","json":"https://secwatch.observer/filing/0001104659-26-029588.json","markdown":"https://secwatch.observer/filing/0001104659-26-029588.md","text":"https://secwatch.observer/filing/0001104659-26-029588.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926029588/0001104659-26-029588-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926029588/avbp-20260317x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T10:56:43.052860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}